CelLBxHealth plc

Research CelLBxHealth plc (CLBX) on Bullrun: market cap GBX 1.51B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is GBX 1.51B.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025GBP 1.35M-GBP 19.51M-GBP 9.51M61.6%-0.06GBP 7.35MGBP 1.82MGBP 7.20M
FY2024GBP 2.86M-GBP 14.23M-GBP 13.89M62.2%-0.05GBP 10.43MGBP 4.21MGBP 18.44M
FY2023GBP 2.19M-GBP 20.13M-GBP 15.12M69.9%-0.08GBP 16.22MGBP 4.55MGBP 22.94M
FY2022GBP 1.04M-GBP 21.69M-GBP 17.94M58.9%-0.09GBP 31.90MGBP 5.00MGBP 40.06M
FY2021GBP 1.01M-GBP 15.01M-GBP 15.80M70.2%-0.07GBP 31.84MGBP 2.34MGBP 40.33M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-17GBX 1.51Bn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 GBX.

About CelLBxHealth plc

CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix platform, emables real-time multiomic insights from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is CelLBxHealth plc's market cap?

CelLBxHealth plc's market capitalization is GBX 1.51B.

What does CelLBxHealth plc do?

CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix platform, emables real-time multiomic insights from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology.